389 related articles for article (PubMed ID: 21470108)
1. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
Meyer CH; Helb HM; Eter N
Ophthalmologe; 2008 Feb; 105(2):125-38, 140-2. PubMed ID: 18256841
[TBL] [Abstract][Full Text] [Related]
3. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept in wet AMD: specific role and optimal use.
Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
[TBL] [Abstract][Full Text] [Related]
6. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Csaky K; Do DV
Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
[TBL] [Abstract][Full Text] [Related]
8. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
9. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Bressler SB
Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
[TBL] [Abstract][Full Text] [Related]
10. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
You JY; Chung H; Kim HC
Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
[TBL] [Abstract][Full Text] [Related]
12. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
16. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
Roller AB; Amaro MH
Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
19. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
20. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
